Geode Capital Management’s Arcus Biosciences RCUS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $48.7M | Buy |
2,252,367
+345,022
| +18% | +$7.45M | ﹤0.01% | 1506 |
|
|
2025
Q4 | $45.5M | Buy |
1,907,345
+308,936
| +19% | +$6.3M | ﹤0.01% | 1545 |
|
|
2025
Q3 | $21.7M | Buy |
1,598,409
+2,080
| +0.1% | +$21.6K | ﹤0.01% | 1960 |
|
|
2025
Q2 | $13M | Buy |
1,596,329
+207,097
| +15% | +$1.77M | ﹤0.01% | 2181 |
|
|
2025
Q1 | $10.9M | Buy |
1,389,232
+179,619
| +15% | +$2.08M | ﹤0.01% | 2236 |
|
|
2024
Q4 | $18M | Sell |
1,209,613
-12,593
| -1% | -$206K | ﹤0.01% | 2021 |
|
|
2024
Q3 | $18.7M | Sell |
1,222,206
-10,869
| -0.9% | -$171K | ﹤0.01% | 2013 |
|
|
2024
Q2 | $18.8M | Buy |
1,233,075
+61,107
| +5% | +$986K | ﹤0.01% | 1961 |
|
|
2024
Q1 | $22.1M | Buy |
1,171,968
+29,799
| +3% | +$515K | ﹤0.01% | 1871 |
|
|
2023
Q4 | $21.8M | Buy |
1,142,169
+64,576
| +6% | +$1.03M | ﹤0.01% | 1854 |
|
|
2023
Q3 | $19.3M | Buy |
1,077,593
+48,671
| +5% | +$978K | ﹤0.01% | 1846 |
|
|
2023
Q2 | $20.9M | Buy |
1,028,922
+50,755
| +5% | +$966K | ﹤0.01% | 1826 |
|
|
2023
Q1 | $17.8M | Buy |
978,167
+31,694
| +3% | +$606K | ﹤0.01% | 1880 |
|
|
2022
Q4 | $19.6M | Buy |
946,473
+35,115
| +4% | +$966K | ﹤0.01% | 1788 |
|
|
2022
Q3 | $23.8M | Buy |
911,358
+65,963
| +8% | +$1.74M | ﹤0.01% | 1604 |
|
|
2022
Q2 | $21.4M | Buy |
845,395
+47,853
| +6% | +$1.17M | ﹤0.01% | 1723 |
|
|
2022
Q1 | $25.2M | Buy |
797,542
+28,030
| +4% | +$939K | ﹤0.01% | 1730 |
|
|
2021
Q4 | $31.1M | Sell |
769,512
-13,664
| -2% | -$530K | ﹤0.01% | 1667 |
|
|
2021
Q3 | $27.3M | Buy |
783,176
+11,622
| +2% | +$362K | ﹤0.01% | 1742 |
|
|
2021
Q2 | $21.2M | Buy |
771,554
+60,032
| +8% | +$1.71M | ﹤0.01% | 1922 |
|
|
2021
Q1 | $20M | Buy |
711,522
+65,431
| +10% | +$2.28M | ﹤0.01% | 1882 |
|
|
2020
Q4 | $16.8M | Buy |
646,091
+30,237
| +5% | +$732K | ﹤0.01% | 1833 |
|
|
2020
Q3 | $10.6M | Buy |
615,854
+63,165
| +11% | +$1.41M | ﹤0.01% | 1909 |
|
|
2020
Q2 | $13.7M | Buy |
552,689
+112,048
| +25% | +$3.02M | ﹤0.01% | 1747 |
|
|
2020
Q1 | $6.12M | Buy |
440,641
+45,647
| +12% | +$568K | ﹤0.01% | 2022 |
|
|
2019
Q4 | $3.99M | Buy |
394,994
+9,907
| +3% | +$83.3K | ﹤0.01% | 2594 |
|
|
2019
Q3 | $3.5M | Buy |
385,087
+154,732
| +67% | +$1.24M | ﹤0.01% | 2599 |
|
|
2019
Q2 | $1.83M | Buy |
230,355
+27,360
| +13% | +$274K | ﹤0.01% | 3006 |
|
|
2019
Q1 | $2.54M | Buy |
202,995
+21,823
| +12% | +$237K | ﹤0.01% | 2707 |
|
|
2018
Q4 | $1.95M | Buy |
181,172
+83,193
| +85% | +$971K | ﹤0.01% | 2788 |
|
|
2018
Q3 | $1.36M | Buy |
97,979
+18,748
| +24% | +$239K | ﹤0.01% | 3087 |
|
|
2018
Q2 | $969K | Buy |
+79,231
| New | +$1.24M | ﹤0.01% | 3201 |
|
Other funds holding RCUS
GS
SCM
VPM
VCM
WP
SL
Geode Capital Management's RCUS Position: Q1 2026 in Review
Geode Capital Management increased its Arcus Biosciences (RCUS) stake by 18% in Q1 2026, buying an estimated $7.45M and bringing the position to 2,252,367 shares worth $48.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1506.
Geode Capital Management first reported a position in RCUS in Q2 2018 and has held it in 32 quarters since. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.
- Geode Capital Management held 2,252,367 shares of Arcus Biosciences worth $48.7M as of Q1 2026.
- Geode Capital Management bought 345,022 Arcus Biosciences shares in Q1 2026, an estimated $7.45M.
- Arcus Biosciences made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #1506 holding.
- Geode Capital Management first reported a position in Arcus Biosciences in Q2 2018 and has held it in 32 quarters since.
- 210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.
Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.